Press Release : Roche to present updated data -2-

receptors. By inhibiting PD-L1, Tecentriq may enable the activation of 
T-cells. Tecentriq is a cancer immunotherapy that has the potential to 
be used as a foundational combination partner with other immunotherapies, 
targeted medicines and various chemotherapies across a broad range of 
cancers. The development of Tecentriq and its clinical programme is 
based on our greater understanding of how the immune system interacts 
with tumours and how harnessing a person's immune system combats cancer 
more effectively. 
 
   Tecentriq is approved in the US, EU and countries around the world, 
either alone or in combination with targeted therapies and/or 
chemotherapies in various forms of non-small cell lung cancer, small 
cell lung cancer, certain types of metastatic urothelial cancer, in 
PD-L1-positive metastatic triple-negative breast cancer and for 
hepatocellular carcinoma. In the US, Tecentriq is also approved in 
combination with Cotellic(R) (cobimetinib) and Zelboraf(R) (vemurafenib) 
for the treatment of people with BRAF V600 mutation-positive advanced 
melanoma. 
 
   About Avastin 
 
   Avastin is a prescription-only medicine that is a solution for 
intravenous infusion. It is a biologic antibody designed to specifically 
bind to a protein called VEGF that plays an important role throughout 
the lifecycle of the tumour to develop and maintain blood vessels, a 
process known as angiogenesis. Avastin is designed to interfere with the 
tumour blood supply by directly binding to the VEGF protein to prevent 
interactions with receptors on blood vessel cells. The tumour blood 
supply is thought to be critical to a tumour's ability to grow and 
spread in the body (metastasise). 
 
   About Roche in cancer immunotherapy 
 
   For more than 50 years, Roche has been developing medicines with the 
goal to redefine treatment in oncology. Today, we're investing more than 
ever in our effort to bring innovative treatment options that help a 
person's own immune system fight cancer. 
 
   By applying our seminal research in immune tumour profiling within the 
framework of the Roche-devised cancer immunity cycle, we are 
accelerating and expanding the transformative benefits with Tecentriq to 
a greater number of people living with cancer. Our cancer immunotherapy 
development programme takes a comprehensive approach in pursuing the 
goal of restoring cancer immunity to improve outcomes for patients. 
 
   To learn more about the Roche approach to cancer immunotherapy please 
follow this link: 
 
   https://www.globenewswire.com/Tracker?data=ue-zypm4c9AFTUlwei0mh9Pdo_OA1jKS5azCmL7Xq_uCXXBBlvyOCtEadbhFAyLtDY9TSsHj9AWmwGNLgwVumP41eYJpFGI38tXJrqcmG2Z8BwMc3kkLfFdymaSZM_an-y-fwX7qum1uTYhFHvY2OOthE4oq6r4Yh-CahQTmCK0r_-C4cTojd1C2BFjlAXNUndRekStHSDsLy1xClFZAM1ltS3iXVsYuBTk7iLxc_8foKnA3mqawTFjdoLeB6aby0FtDhQFdn2pdXFAwtVl3WeuNguk78D6WThQgGWPGtS9KKHce6YulTPybOvrEViph 
http://www.roche.com/research_and_development/what_we_are_working_on/oncology/cancer-immunotherapy.htm 
 
 
   About Roche 
 
   Roche is a global pioneer in pharmaceuticals and diagnostics focused on 
advancing science to improve people's lives. The combined strengths of 
pharmaceuticals and diagnostics under one roof have made Roche the 
leader in personalised healthcare -- a strategy that aims to fit the 
right treatment to each patient in the best way possible. 
 
 
 
   Roche is the world's largest biotech company, with truly differentiated 
medicines in oncology, immunology, infectious diseases, ophthalmology 
and diseases of the central nervous system. Roche is also the world 
leader in in vitro diagnostics and tissue-based cancer diagnostics, and 
a frontrunner in diabetes management. 
 
 
 
   Founded in 1896, Roche continues to search for better ways to prevent, 
diagnose and treat diseases and make a sustainable contribution to 
society. The company also aims to improve patient access to medical 
innovations by working with all relevant stakeholders. More than thirty 
medicines developed by Roche are included in the World Health 
Organization Model Lists of Essential Medicines, among them life-saving 
antibiotics, antimalarials and cancer medicines. Moreover, for the 
twelfth consecutive year, Roche has been recognised as one of the most 
sustainable companies in the Pharmaceuticals Industry by the Dow Jones 
Sustainability Indices (DJSI). 
 
 
 
   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2019 employed about 98,000 people worldwide. In 
2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 
61.5 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit 
https://www.globenewswire.com/Tracker?data=Xu1pOKroa2SSSjgaktwFPUmDAP52VpCpa3C54f3Vtup6z2Xw6qw44lOvVDM2Go04_LAC1eulvClCd-cIHeRCBw== 
www.roche.com. 
 
 
 
   All trademarks used or mentioned in this release are protected by law. 
 
 
 
   References 
 
   [1] Llovet JM et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 
2016;2:16018. 
 
   [2] World Health Organisation. Globocan 2020 -- Liver cancer factsheet. 
[Internet; cited 2020 December] Available from: 
https://www.globenewswire.com/Tracker?data=ue-zypm4c9AFTUlwei0mh61Wijaj2C7XvrToGR3jYqvVeCToz0uQWhxm33BiAGEvC1UVJjF0oaM8Wyydg_M2GgHzJVJXQM_wLRrxGQs6Xw4bFzQh6Uttogwzz0vNWI-OFrTG0r33cLfGAFMTxQ2l00UYRcFAEzdaPKyKWeR7aGxYT5ZOwVIFWf_p8BVG9_SiFjuqB9DOYdadM1UWPe36mbUQViIYyaYrSL2sRNCXPwU= 
http://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf 
 
 
   [3] World Health Organisation. Globocan 2020 -- China factsheet. 
[Internet; cited 2020 December] Available from: 
https://www.globenewswire.com/Tracker?data=ue-zypm4c9AFTUlwei0mh61Wijaj2C7XvrToGR3jYqvVeCToz0uQWhxm33BiAGEvswaPCwpAS02U4DL9T_ZoqoIOopxp3C2KaT7TR5TvWK42y1JaSqD5CxXRvWklKoA46mvmQ-4bDwY81xiRX_6M4fMaowsND-xuj2hfp21EjK44kpK46jWjrI_zFdlKl0QVIiiX9QjNooUeznbTTSylp5cKnl1sIBTsxAwQxermNzoUWtioSUe4chOCxtpAqMU2 
http://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf 
 
 
   [4] American Cancer Society. Key statistics about liver cancer. 
[Internet; cited 2020 October] Available from: 
https://www.globenewswire.com/Tracker?data=ue-zypm4c9AFTUlwei0mh_TzN6CiVlOjuStVPlFvC7YXE33kPwL4-H1dIFF4YiqJScijRtENfb1NUjcdkayC1dXeDJNuOozk5F1eVppSxgcT_cCa66AXTFGxBbdsFErNzUzarTz6PNrofXLT42vJFCtPp6PwWI5oM7KevN8xgfEEX7iIuSFiRsv6TcIGK8RNLhq6zmEn5pBflkjKn2C0q4sYXgG6aHIfChHBffzjmCyYnTsW_H_oQAFe4qZwH1MO 
https://www.cancer.org/cancer/liver-cancer/about/what-is-key-statistics.html 
 
 
   [5] Rawla P et al. Update in global trends and aetiology of 
hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22(3):141-150. 
 
   [6] Pimpin L et al. Burden of liver disease in Europe: Epidemiology and 
analysis of risk factors to identify prevention policies. J Hepatol. 
2018;69(3):718-735. 
 
   [7] World Health Organisation. Globocan 2020 -- Europe factsheet. 
[Internet; cited 2020 December] Available from: 
https://www.globenewswire.com/Tracker?data=ue-zypm4c9AFTUlwei0mh9WnLqY-BdnmuofIzH5FLMHr4W0x7vOKoJDVbsNcwyIlV0-wvkfEVL4Ho_iz1Zn3LiNo5DrNCdGNjY8sdACr2MkdeZlak2OIxcbCo5mjUrH2OxBvVUKUs46pvRb6YBbZ8sn7HqUDIAO3DN0trDpbovMULvFbk0MS659Em4RSFcNQGTxdILpWyvoOxgWrVRMyfhJQMQDEZDZ6ZJ_fkAYP9wtAWIbQwEyztAdfzmrBlxyK 
https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf 
 
 
   [8] Giannini EG et al. Prognosis of untreated hepatocellular carcinoma. 
Hepatology. 2015;61(1):184-190. 
 
 
 
 
 
   Roche Group Media Relations 
 
   Phone: [phone] / e-mail: 
https://www.globenewswire.com/Tracker?data=jd3gO_t6MwPtjD6ACCs1RoZl7XvDQ8WfC8FtCC54WzOptrwYF9lTW_uOiJW4AgK-He-_cXKAaBpTPjCKV9O5bfNFjQd0GK8L_pCLdOXab1EgbkTVI8rcInom64-XSRfZ 
[e-mail] 
 
 
 
 
 
 
 
 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: [phone]     Phone: [phone] 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: [phone]     Phone: [phone] 
Nina Mählitz           Nathalie Meetz 
 Phone: [phone]     Phone: [phone] 
Dr. Barbara von Schnurbein 
 Phone: [phone] 
 
 
 
 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]          e-mail: mailto:[e-mail] 
 [e-mail]                         [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]   e-mail: mailto:[e-mail] 
 [e-mail]                  [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]       e-mail: mailto:[e-mail] 
 [e-mail]                      [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
Investor Relations North America 
Loren Kalm                                    Dr. Lisa Tuomi 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]            e-mail: mailto:[e-mail] 
 [e-mail]                           [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
 
 
   Attachment 
 
 
   -- 12012021_MR_IMbrave150 study_en 
      https://ml-eu.globenewswire.com/Resource/Download/499623f5-0fb1-454e-a03e-5568d2e490eb

(END) Dow Jones Newswires

January 12, 2021 01:00 ET (06:00 GMT)